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Summary 
Recent in vitro studies have documented that thromboxane (Tx)A2 induces thymocyte apoptosis 
by acting on specific receptors abundantly expressed on the surface of immature T lymphocytes. 
No information is available on the in vivo relevance of this observation in development of self- 
or acquired tolerance. We and others have previously documented that injection of donor cells 
into adult thymus of experimental animals induced specific systemic unresponsiveness to allografts 
in the rat and mouse models. More recently, we have shown that intrathymic injection of synthetic 
class  II  major  histocompatibility complex  (MHC)  allopeptides  resulted  in  donor-specific 
unresponsiveness to renal allografts. The induction of unresponsiveness was abrogated by recipient 
thymectomy within the first week. We now report the effect of TxA~ blockade on acquired 
thymic tolerance to renal allografts induced by intrathymic injection of synthetic class II MHC 
allopeptides  in the Wistar-Furth (WF) to Lewis rat strain combination. Administration of the 
TxA2 receptor blocker prior to transplantation or 2 wk postengraftment completely abrogated 
the  unresponsive  state.  In  addition,  inhibiting  the  TxA2-forming  enzyme  by  aspirin  or 
dexamethasone also abolished the induction of acquired thymic tolerance. Evidence is also provided 
for a critical "dose" of peptides to be injected into the thymus to induce systemic unresponsiveness 
to renal allografts.  These data,  coupled with observations that activated peripheral T  cells can 
circulate  through the thymus, provide evidence  that TxA2/TxA2 receptor interaction in the 
thymic microenvironment, leading to anergy/programmed cell death of activated T cells, may 
play an important role in the development of acquired  unresponsiveness in vivo. 
I 
n a previous study, we have shown that intrathymic injec- 
tion of allogenic cells (glomeruli or peripheral mononuclear 
cells) into MHC incompatible recipients allowed long-term 
survival of a subsequent kidney graft from the same donor 
strain but not from a third party donor (1, 2). More recently 
we have shown that thymic recognition ofimmunogenic  class 
II MHC allopeptides is sufficient to achieve systemic unrespon- 
siveness and prolong allograft  survival  in high responder 
Wistar-Furth (WF) (R.T1  u) to Lewis rat strain combinations 
(3, 4). Early (within 1 wk) but not late (after 2 wk) thymec- 
tomy abolishes this unresponsive state, indicating the central 
role of the thymus in the process of induction of acquired 
systemic tolerance to alloantigens in this model. 
There are two recognized mechanisms by which T  cells 
are rendered tolerant to self-antigens  during their matura- 
tion  in  the  thymus:  one  is  apoptosis,  which  physically 
eliminates reactive T cell clones; the other one is clonal anergy, 
which functionally inactivates T cells (5-7). Both mechanisms 
can operate in the thymus, where given the cellular hetero- 
geneity of thymic microenvironment variable degrees of apop- 
toffs may be associated with anergy (7). However the com- 
plexity of cellular interactions underlying these events and 
the soluble mediators involved in the communication that 
ultimately generates  tolerance have not been established. 
That thymic microenvironment plays a major role in au- 
toreactive T cell elimination is supported, among other demon- 
strations,  by studies that clonal deletion does not occur in 
nude mice (which congenitally lack the thymus) (6). It also 
appears that soluble factors establish whether a given clone 
is suppressed or will mature to a functional T cell and leave 
the thymus as such. The observation that maturing thymo- 
cytes, in the earliest  stage of T  cell development, but not 
1967  J.  Exp.  Med.  ￿9  The Rockefeller  University Press ￿9 0022-1007/94/11/1967/06 $2.00 
Volume 180  November 1994  1967-1972 later on, have very high cell surface expression of receptors 
for thromboxane (Tx)A2 (8), a potent aggregating agent and 
vasoconstrictor  (9),  suggested  that  TxA2  elaborated  by 
thymic stromal cells might act as the key signal for cellular 
events related to T  cell development. TxA2 is the ideal mes- 
senger for cell-cell interaction in the thymus for at least two 
of its properties: (a) it is synthesized and released upon cell 
activation; and (b) has an half-life as short as 30 s (9) so that 
its effect is confined to those very cells close enough to the 
ones initially activated. TxA2 binding to its specific receptors 
on cell membranes  activates protein kinase C  and increases 
intraceUular  calcium  as  the result  of phosphatidyl inositol 
breakdown (9-12).  It is relevant here that both protein ki- 
nase C  activation and enhanced intracellular calcium are the 
two single events that in developing thymocytes serve to pro- 
mote DNA fragmentation and apoptosis (13-15). Recent data 
indicate that  a TxA2 agonist  (but  not  an inactive metabo- 
lite), induced concentration-dependent DNA fragmentation 
in CD4 + CD8 § cells (8), which was inhibited by a specific 
antagonist. We now present direct evidence based on in vivo 
experiments that TxA2 mediates  acquired unresponsiveness 
to renal allograft induced by thymic recognition of donor 
MHC  allopeptides. 
Materials  and  Methods 
Materials.  BMS 180291 (1S-(lc~, 2or, 3o~, 4)-2-[[3-[4-[(pentyl- 
amino)carbonyl]-2-oxazolyl]-7-oxabicyclo  [2.2.1] hept-2  -yl]  methyl] 
benzenepropanoic acid) was a gift from Bristol-Myers Squibb Phar- 
maceutical Research Institute (Princeton, NJ). Sequences of eight 
overlapping WF peptides of 25 amino acids each (1-25, 20-44, 39-64, 
and 68-92 for RT1.B, and 1-25, 20-44, 39-64, and 60-84 for RT1.D) 
were recently published (16). 
Kidney Transplantation.  Orthotopic rat renal transplants were 
performed as previously described (2). Briefly, ether anesthesia was 
used throughout. The WF donor left renal vein was anastomosed 
end to end to the recipient Lewis left renal vein. The donor renal 
artery was anastomosed to the aorta with the small patch of donor 
aorta, while the left ureter of donor rats was pulled through the 
posterior wall of the dome of the bladder. The right kidney of the 
recipient was then removed. Ischemic time ranged from 20 to 40 
rain (mean 30 min). 
TxA2 ReceFtor Blockade and Acquired Thymic Tolerance.  Adult 
male Lewis (ILT11) rat recipients (225-250 g body weight) were 
given the TxA2 receptor antagonist BMS 180291 (10 mg/kg twice 
daily orally) or vehicle. BMS 180291 is a potent, highly selective 
antagonist of TxA2/prostaglandin endoperoxide receptors which 
is long-acting when given orally to experimental animals including 
rats (17). Evidence for specific activity is based  on inhibition of 
platelet aggregation, and contraction of trachea or aorta induced 
by a TxA2 mimetic but not other agonists  (17). 4 h later, the same 
animals  were injected intrathymically (50 #g in each lobe) with 
a mixture of class II MHC allopeptides from a MHC-incompatible 
WF (RT1 u) rat. Four overlapping peptides of 25 amino acids for 
each locus were synthesized using published sequences of tLT1.B~ 
and RT1.DB distal domains of tLT1  u (WF) dissolved in PBS (16). 
The animals received no immunosuppressive drugs. After 48 h they 
underwent bilateral nephrectomy, and received a WF (RT1  u) renal 
allograft.  Treatment with the TxA2 receptor antagonist or vehicle 
was continued daily thereafter. Animals were housed in metabolic 
cages and monitored for daily urine output. Allograft rejection was 
defined as anuric renal failure. Renal allograft function was assessed 
by measuring serial serum creatinine levels at different intervals post- 
transplantation.  Serum was obtained by tail vein puncture and serum 
creatinine was measured by the alkaline picrate method (18). 
Additional experiments with the TxA2 receptor antagonist  were 
performed starting the treatment 15 d after transplantation  (n =  5). 
Preparation of Spleen Cells and AdoFtive Transfer  Experiments.  The 
spleen was teased through a 500./~m gauge sieve  into a 10-ml falcon 
tube, and the large particles were allowed to settle. The superna- 
tant was centrifuged at 400 g  for 10 min, and the cells washed 
twice  in  PBS.  Contaminating  red  blood  cells  were  lysed  by 
resuspending the cells in 2 ml of Tris-HC1 (17 mM), pH 7.2, con- 
taining 0.16 M ammonium chloride,  incubated at room tempera- 
ture for 5 min. The suspension  was then diluted to 50 ml with 
0.1% bovine serum albumin in PBS, and centrifuged at 400 g for 
10 min. The cells were washed twice in PBS and resuspended  in 
0.5%  (wt/vol) BSA/PBS. Immediately before intravenous injec- 
tion into the Lewis recipient animals,  the cells were washed and 
resuspended in saline. To investigate whether unresponsiveness  to 
kidney allograft involved a suppressor  effector mechanism, adop- 
tive transfer experiments were performed. Two Lewis rats injected 
in the thymus with WF class II MHC allopeptides  mixture and 
with kidney graft surviving >300 d were killed  and their spleen 
removed. After isolation of spleen cells from the two rats they were 
pooled and injected intravenously (100 x  106 cells) in native Lewis 
rats (n  =  3). 48 h later they were bilaterally nephrectomized and 
were transplanted orthotopically with MHC incompatible WF 
kidney. Graft survival was monitored as above. As control the same 
experiments were performed in Lewis rats (n  =  3) injected with 
splenocytes  from normal Lewis animals. 
We also evaluated whether reducing the amount of peptide mix- 
ture injected into the thymus allowed permanent engraftment of 
the subsequent kidney allograft. Lewis rats  received intrathymi- 
cally I (n =  4) or 10 (n =  4) #g of the WF MHC peptide mixture 
48 h before transplantation of the WF kidney into the left ortho- 
topic site. Graft survival  was evaluated  thereafter. 
Mixed LymFhocyte Response (MLR) Assay.  Lymphocytes (PBLs) 
isolated from peripheral blood of responder Lewis and stimulator 
WF rats were suspended in RPMI 1640 medium (GIBCO BILL, 
Gaithersburg, MD) supplemented with L-glutamine (2 mM), pen- 
icillin  (100 U/ml),  streptomycin (100/~g/ml),  and 10%  FCS%. 
The MLRs were set up by culturing an equal number of Lewis 
responder cells and irradiated (3,000 rads) WF stimulator cells in 
96-well U-bottom plates at 37~  with 5% CO2 for 4 d. Prolifer- 
ation was assayed by [3H]thymidine uptake and relative response 
was calculated  as previously described  (16). 
Statistical Analysis.  Results are expressed as mean _+ SD. Data 
were analyzed by t test or by one way analysis of variance (repeated 
measures) with Fisher's protected least significance difference, and 
Dunnett's test for multiple comparisons, as appropriate.  Statistical 
significance  level was defined as p <0.05. 
Results and Discussion 
Effect of YxA2 Receptor Blockade on Acquired Thymic Toler- 
ance.  Lewis rats given vehicle and injected intrathymically 
with the MHC allopeptide mixture did not reject their grafts 
and are surviving (>110 d; Table 1). By contrast, rats treated 
with the TxA2 receptor blocker and injected with the pep- 
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Vehicle on Kidney Allografi  Survival in Lewis Rat Recipients 
Injected Intrathymically with MHC-WF Allopeptide Mixture 
Graft  survival  Median 
d  d 
BMS 180291  6,  7, 6,  6,  6  6 
Aspirin  7,  7,  7, 8,  9,  10  7.5 
Dexamethasone  6,  7,  7,  7,  9,  9  7 
Vehicle  >110,  >110 >110,  >110  >110 
2013OO 
1,5000 
E 
10000 
500O 
0 
[] Vet-~.le 
I~I BMS 180~91 
I  I 
Figure 2.  Proliferation  of peripheral blood lymphocytes from Lewis 
recipients of WF renal allografts injected  intrathymicaUy  with class II MHC 
peptide mixture and given vehicle or BMS 180291, in the standard one- 
way mixed lymphocyte  response. Values are mean + SD, *p <0.01 vs. 
vehicle. 
tides rejected their  allografts within  6-7 d  (Table  1).  30 d 
after transplant,  renal grafts in untreated rats injected with 
the peptide mixture were functioning well, as documented 
by serum creatinine (0.62  _+ 0.05 mg/dl) compared with age- 
and  sex-matched control  rats  (Fig.  1).  In rats  given BMS 
180291, however, serum creatinine was elevated when anuria 
developed (2.94  _+  0.15 mg/dl).  To establish the functional 
status of alloreactive T cells of transplanted animals injected 
intrathymically with the peptides, peripheral blood lympho- 
cytes from rats treated with BMS 180291  (on day 8-10) or 
vehicle-treated rats were tested in vitro for their  ability to 
proliferate to WF stimulator cells in the standard one-way 
MLR (3). MLR proliferation was significantly (p *(0.01) re- 
duced in tolerant animals, but a high MLR proliferative re- 
sponse was found in rats receiving the TxA2 receptor blocker, 
which rejected the kidney (Fig.  2). 
In an additional group of rats injected intrathymically with 
peptide mixture,  BMS 180291  treatment  was started  15 d 
after transplantation.  At that  time renal grafts were func- 
tioning well, as documented by serum creatinine concentra- 
tion within the normal range (0.58  _+  0.07 mg/dl).  3-6 d 
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Figure  1.  Time course of renal allograft function after intrathymic 
injection of class II MHC allopeptides in Lewis rat  recipients given 
BMS 180291, aspirin, dexamethasone, or vehicle. Values are mean _+ SD. 
*p <0.01 vs. vehicle at the same time point, and at day 30 after kidney 
transplantation. 
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after beginning  the TxA2 receptor  antagonist,  the animals 
had a sudden decline in renal function and invariably rejected 
their kidneys within  10 d.  Individual  graft survival was 5, 
6, 7, 9, and 10 d. When the animals developed oliguria serum 
creatinine level was 2.87  +_ 0.21 mg/dl. Findings that BMS 
180291 treatment eliminated thymic unresponsiveness in vivo 
and enhanced alloreactivity to donor lymphocytes in vitro 
would indicate that blocking TxA2 activity into the thymus 
inhibits the intracellular  events that result in functional anergy 
or apoptosis of aUoreactive  T  cells. 
Altogether these data suggest that TxA2 is at least one of 
the soluble factors regulating events in the thymus that follow 
recognition of antigenic material (either self-antigens or allo- 
peptides)  leading to systemic unresponsiveness.  TxA2 forming 
enzymes are expressed in thymic stromal cells, including epi- 
thelial  and dendritic cells.  Recent data by Agus et al.  (19) 
indicate that activated but not resting peripheral T cells cir- 
culate  through  the  thymus.  These  observations provide  a 
potential mechanism  to explain the events that  lead to ac- 
quired thymic tolerance in our model. We suggest that MHC- 
peptide recognition by aUoactivated T cells circulating  through 
the thymus presented by thymic antigen-presenting cells leads 
to a series  of events that  involve the TxA2/TxA2  receptor, 
thus triggering intracellular events that increase cytoplasmic 
calcium resulting  in T  cell anergy and ultimately deletion 
by apoptosis. This is consistent with our recent observation 
that although in vivo administration of recombinant (r)IL-2 
abrogates the induction of the unresponsive state, it had no 
effect when administered in the maintenance phase of toler- 
ance (4). 
Effect of Cyclooxygenase Inhibitors on Acquired Thymic Toler- 
ance.  TxA2  is  synthesized  via  cydooxygenase,  the  key 
regulatory enzyme of eicosanoid cascade (9,  10).  Cycloox- 
ygenase is present in all cell types and transforms arachidonic 
acid into  unstable endoperoxide prostaglandin  G2  (PGG2) 
and prostaglandin  H2 (PGH2) (20).  Formation  of biologi- 
caUy active TxA2 from PGH2 occurs through  the action of 
an additional enzyme called TxA2 synthase (9, 20). Two iso- 
forms of cyclooxygenase enzyme exist, a constitutive one and 
an inducible one (21). Cytokines and growth factors upregu- 
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of neonatal mice (22,  23) and participates in the early phase 
of thymocyte maturation  by  promoting  the  synthesis  of 
prostaglandins. To identify the specific enzyme involved in 
TxA2-mediated unresponsiveness upon thymic recognition of 
alloantigens, we have introduced a further pharmacological 
manipulation by giving to Lewis rats aspirin (100 mg/kg/day 
orally) or glucocorticoids (dexamethasone: 2.5  mg/kg/day 
subcutaneously) from the day of intrathymic injection of the 
MHC allopeptide mixture, and transplanting an incompat- 
ible WF kidney into them 48 h later.  Aspirin by acetylating 
serine-530 of the prostaglandin H  synthase molecule aspe- 
cifically inhibits both the constitutive and inducible cyclooxy- 
genase enzymes (21), whereas glucocorticoids selectively in- 
hibit the inducible but not the constitutive form (24,  25). 
This has been documented in vitro in human dermal fibro- 
blasts (26) and cultured monocytes (27), and in vivo in mice 
concurrently treated with intravenous lipopolysaccharide (24). 
By contrast the activity of TxA2 synthase enzyme is not in- 
hibited by aspirin nor by glucocorticoids (28). 
All animals pretreated with aspirin rejected the graft within 
7-10 d (Table 1), with severe renal failure as documented by 
high serum creatinine (3.15  _+  0.06 mg/dl) the day before 
they became anuric (Fig.  1). Similarly, after daily dexameth- 
asone the kidney allograft failed within 6-9 d (Table 1). At 
the time of graft rejection, serum creatinine was again elevated 
(3.04  _+ 0.11 mg/dl) (Fig. 1). The fact that both aspirin and 
dexamethasone eliminate renal aUograft unresponsiveness medi- 
ated by thymic recognition of class II MHC peptides might 
indicate that  upregulation  of inducible cyclooxygenase in 
stromal cells, the only cell population in the thymus expressing 
the enzyme, is instrumental in generating cellular events (T 
cell apoptosis or functional anergy) that promote tolerance 
in the long run. The present data have major implications 
for future studies that might be planned to investigate the 
feasibility of the thymic technique to  induce tolerance in 
humans. One option that has been considered by most inves- 
tigators so far is the use the thymus inoculation of donor 
cells or peptides in association with conventional immunosup- 
pression to start with, in order to avoid that a failure of the 
thymus procedure exposes the patients to an acute irrevers- 
ible rejection. From the present data, it is clear that glucocor- 
ticoids interfere with the mechanism(s) that allow to achieve 
thymic tolerance. This has therefore to be considered when 
planning human studies. 
Effect of  Adoptive Transfer  Experiments on Graft Survival.  In 
our model intrathymic injection of class II MHC allopep- 
tides alone was sufficient to induce unresponsiveness to class 
I and class II MHC incompatible renal allografts. Induction 
of tolerance through indirect T  cell recognition of alloan- 
tigens (29),  also called "dominant tolerance" has been ob- 
served in the cardiac allograft model of tolerance with sys- 
temic injection of class I MHC  transfected L cells  (30)  in 
the mouse and intrathymic injection of soluble class I MHC 
molecules (31) in the rat. Such a state of dominant tolerance 
may suggest thepresence of a regulatory or suppressor effector 
mechanism. To investigate this possibility we performed adop- 
tive transfer experiments. A single intravenous dose of spleen 
cells from long-term kidney graft-tolerized Lewis rats injected 
into naive Lewis rats that received a WF kidney allograft 48 h 
later failed to prolong renal graft survival.  Thus in all kidney 
recipients the graft was invariably rejected within 7-9 d (me- 
dian graft survival:  7 d). Similarly,  Lewis rats injected intra- 
venously with spleen cells from normal Lewis rats rejected 
a subsequent WF kidney allograft within 10 d (median graft 
survival:  8 d). In both group of rats serum creatinine was 
elevated at the time of the development of anuria (3.07  +_ 
0.18 and 3.15  _+  0.13 mg/dl). These findings suggest that 
the state of tolerance is not due to the presence of suppressor 
cells, but indicate that the effector mechanisms are most likely 
related to apoptosis of functionally anergic T cells that circu- 
late through the thymus (4,  19,  32). 
Evidence That Acquired Thymic Unresponsiveness to Renal Al- 
Iografi Is Dependent on  the Dose of Peptides Injected into the 
Thymus.  Our initial studies showed that a single intrathymic 
injection of 100 #g of a mixture of eight synthetic RT1.Bu~ 
plus RT1.Du3 allopeptides into adult male Lewis rats 48 h 
before receiving MHC-incompatible WF vascularized renal 
allograft induced antigen-specific unresponsiveness and pro- 
longed renal allograft survival (3).  Recent evidence has be- 
came available that the amount of self-antigens presented to 
maturing  thymocytes by stromal cells within  the thymic 
microenvironment is  critical  for  determining  the  fate of 
CD4+8 + immature thymocytes (33).  Thus high concentra- 
tion of these peptides activates the series of events at the early 
stages  of thymocyte development ultimately leads to nega- 
tive selection of potentially autoreactive cells. By contrast low 
concentration of the same peptides complexed to self-MHC 
on stromal ceils serves to deliver signals that promote posi- 
tive selection and full maturation of thymocytes to lympho- 
cytes. In our model we tested the tolerogenicity of lower doses 
of the  same class II  MHC  allopeptide mixture.  Animals 
intrathymically injected with  1 and  10 #g  RT1.Bu3  plus 
RT1.Du3 allopeptides and receiving WF kidney allografts 
48 h later acutely rejected their grafts within 12 and 11 d, 
respectively (Table 2). All animals had elevated serum creati- 
nine level at the time of development of anuria (1/~g: 2.99  _+ 
Table  2.  Survival of WF Renal Allografis in Lewis Recipients 
Intrathymically Injected with Lower Doses of Class II MHC 
Allopeptides 
Graft survival  Median 
d  d 
Peptides (1 #g)  7,  11,  11,  12  11 
Peptides (10 #g)  9, 9,  9,  11  9 
1970  Thromboxane  A2 and Acquired Thymic Tolerance 0.15 mg/dl; 10 #g: 2.89  _+ 0.28 mg/dl). These data indicate 
that lowering the dose of allopeptides injected into the thymus 
did not allow permanent engraftment of donor kidney al- 
lograft and suggest that the amount of donor antigen presented 
to T  cells is critical for triggering intracellular events that 
promotes functional anergy and or apoptosis of T  cells. 
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